Description
Fasinumab is a full human IgG1k monoclonal antibody under investigational therapy that targets Nerve Growth Factor (NGF). It interrupts pain signaling pathways and thus alleviates pain and improves function in patients suffering from chronic pain conditions. Manufactured by Regeron and Teva Pharmaceuticals, it designed for the treatment of acute sciatic pain.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Fasinumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Fasinumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Fasinumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Fasinumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!